Investors & Media

John Tsai, M.D., has served on our Board of Directors since January 2023. Dr. Tsai is the Chief Executive Officer of Forcefield Therapeutics and an executive partner at Syncona. Prior to this role, Dr. Tsai was President, Global Drug Development and Chief Medical Officer at Novartis, where he led the company’s development portfolio spanning 160 new projects and 500 clinical trials, as well as the team securing global approvals for 15 new medicines. Dr. Tsai has served as Chief Medical Officer and Senior Vice President of Global Medical Affairs at Amgen and spent the previous 11 years at Bristol-Myers Squibb. During his tenure at Bristol-Myers Squibb, Dr. Tsai held positions of increasing responsibility within the Medical and Drug Development organizations, including Head of Late Phase Development and Oncology Development Leader, Head of Worldwide Medical Affairs, Chief Medical Officer Europe, Head of U.S. Medical, and Vice-President, Cardiovascular and Metabolic Disease Area. Earlier in his career, Dr. Tsai held drug development roles at Pfizer and manufacturing roles at GE. Dr. Tsai received a B.S. in electrical engineering from Washington University in St. Louis and an M.D. from University of Louisville School of Medicine.